If you are confident that the results of your pre-clinical data set will be received favourably by the market (refer to summary contained with rights issue - there are number of pre-clinical data announcements to be made later this month, in February and in the first quarter of this year), why on earth would you want to raise $10million at 1.7c and dilute existing shareholders by nearly 40-50%?
I agree that they will need a larger capital raise. They should be able to do this easily and at a much higher price than these levels, but why rush to do this now?
Certainly if management are pessimistic regarding the near term share price, then raising $10 million + at these levels would make sense. However, you would be silly to do this if you (i.e., management) were privy to further good pre-clinical data results (and potential insurance recoveries)!!
Lets see where the share price heads after further pre-clinical results are released. Not long to wait now!!
- Forums
- ASX - By Stock
- PAB
- Ann: $2.4 Million Fully Underwritten Rights Issue
Ann: $2.4 Million Fully Underwritten Rights Issue, page-31
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 3776088 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 2310786 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 3776088 | 0.006 |
14 | 6266824 | 0.005 |
9 | 7414000 | 0.004 |
6 | 6065682 | 0.003 |
2 | 2770000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 2310786 | 5 |
0.008 | 1521890 | 4 |
0.009 | 960280 | 3 |
0.010 | 126000 | 2 |
0.011 | 80000 | 1 |
Last trade - 16.12pm 18/09/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
Day chart unavailable